This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent

by | May 14, 2025 | Stock Market

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.

Article Attribution | Read More at Article Source